ESMO Congress 2023

Three phase 3 trials have shown improved outcomes with amivantamab combinations in different populations of patients with advanced NSCLC.

Giving induction chemotherapy before chemoradiotherapy significantly boosts the survival of women with locally advanced cervical cancer.

The PSMAfore trial of the radioligand LuPSMA has met its primary endpoint of a radiographic PFS benefit in men with metastatic metastatic castration-resistant prostate cancer.

Datopotamab deruxtecan improves the outcomes of pretreated patients with HR-positive, HER2-negative metastatic breast cancer.

Adjuvant treatment with alectinib confers a significant DFS benefit versus chemotherapy in resectable, ALK-positive non-small-cell lung cancer.

Durvalumab plus chemotherapy followed by maintenance durvalumab with or without olaparib significantly improves the PFS of women with advanced endometrial cancer.

Tarlatamab has demonstrated durable antitumor activity and acceptable safety in previously treated patients with extensive-stage SCLC in the DeLLphi-301 trial.

People with advanced gastric or gastroesophageal junction cancer benefit from the addition of pembrolizumab to first-line trastuzumab plus chemotherapy.

Women who live and work in places with higher levels of particulate matter have a greater risk of developing breast cancer than women who live and work in less polluted areas.

A recent phase II study shows encouraging results for the neoadjuvant treatment of cutaneous squamous cell carcinoma with the PD-1 inhibitor cemiplimab.

Combination treatment with radium-223 and enzalutamide appears to have added value for patients with metastatic castration-resistant prostate cancer in the REASSURE study.

All countries need systematic reporting of diagnostic and therapeutic delays in cancer care, before AI can be adequately deployed to improve care. 

CUPISCO trial results indicate extensive genomic profiling and molecularly guided therapy improve progression-free survival in patients with a cancer of unknown primary.

EVICTION study shows activation of γ9δ2 T cells by the monoclonal antibody ICT01 has the potential to become a novel immunotherapeutic approach for relapsing/refractory hematologic cancers.

NICHE-3 shows promising initial results for neoadjuvant nivolumab plus relatlimab in mismatch repair-deficient colon cancer.

People with untreated resectable non-small-cell lung cancer benefit from the addition of nivolumab to neoadjuvant chemotherapy plus adjuvant treatment with nivolumab.